Europe Medical Cannabis Market, By Product (Oil, Dried Medial Cannabis, Medical Cannabis Capsules, Whole Flower, Ground Flower, Vape Pen, Creams & Moisturizer and Others), Source (Synthetic and Natural), Species (Cannabis Indica, Sativa and Hybrid), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC)/DELTA-8-Tetrahydrocannabinol and Others), Application (Pain Management, Anxiety, Muscle Spasms, Nausea, Appetite Loss, Cancer, Arthritis, Alzheimer's Disease/Migraine, Epilepsy, Depression and Sleep Disorders, Multiple Sclerosis, Autism, Mental Health Conditions, Elevate Mood and Others), Route of Administration (Oral Solutions and Capsules, Smoking, Vaporizers, Topicals and Others), End User (Pharmaceutical Industry, Research and Development Centers, Homecare Settings, Hospital, Rehab Centers and Others), Distribution Channel (B2B and B2C)- Industry Trends and Forecast to 2029.
Market Analysis and Insights
Medical marijuana has also been legalized in other EU member states, most recently in France, Romania, and the Czech Republic. For instance, the use of Sativex has been approved in 17 European countries, nine of which have already made it available.
Legal cannabis is one of the fastest-growing industries in European states, with major implications for food and beverage, textile, chemical and many other industries. For thousands of years, hemp seeds have been used as a nutritional food. These seeds contain very fewer levels of THC (δ-9-tetrahydrocannabinol), and hence, they are different from medicinal marijuana.
Data Bridge Market Research analyses that the Europe medical cannabis market will grow at a CAGR of 29.5% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Product (Oil, Dried Medial Cannabis, Medical Cannabis Capsules, Whole Flower, Ground Flower, Vape Pen, Creams & Moisturizer and Others), Source (Synthetic and Natural), Species (Cannabis Indica, Sativa and Hybrid), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC)/DELTA-8-Tetrahydrocannabinol and Others), Application (Pain Management, Anxiety, Muscle Spasms, Nausea, Appetite Loss, Cancer, Arthritis, Alzheimer's Disease/Migraine, Epilepsy, Depression and Sleep Disorders, Multiple Sclerosis, Autism, Mental Health Conditions, Elevate Mood and Others), Route of Administration (Oral Solutions and Capsules, Smoking, Vaporizers, Topicals and Others), End User (Pharmaceutical Industry, Research and Development Centers, Homecare Settings, Hospital, Rehab Centers and Others), Distribution Channel (B2B and B2C)
|
|
Countries Covered
|
Germany, France, U.K., Spain, Italy, Netherlands, Belgium, Russia, Switzerland and Rest of Europe
|
|
Market Players Covered
|
Tilray, Medipharm Labs, Althea Company Pty Ltd, PharmaHemp, Aurora Cannabis., Elixinol Global Limited, CANOPY GROWTH CORPORATION, Jazz Pharmaceuticals, Inc., ECOGEN BIOSCIENCES, Little Green Pharma, GRASS & CO., CANNARAY, Sanity Group GmbH., VIVO Cannabis Inc., HEXO Corp., and Marrican Inc
|
Market Definition
Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family. For several years, it has been used medicinally and has a wide range of applications in the treatment of various diseases, including chronic pain, cancer, depression, diabetes, arthritis, glaucoma, epilepsy, migraines, AIDS, and Alzheimer’s among others.
Europe Medical Cannabis Market Dynamics
Drivers
- Rise in Geriatric Population
The growing geriatric population across the globe is more susceptible to chronic illness, which require more physician visits. The steadily aging population suffers from various health conditions, including diabetes, depression, and dementia, among others. Medical cannabis has the properties to treat these diseases, and therefore, the growing population is playing a significant role.
The use of medical cannabis is more important in the older adult population due to polypharmacy, health literacy, and accessibility of the application process and dispensary locations.
For instance,
- In September 2021, the scientific research by Lancet stated the elderly population aged over 64 years in Europe had used medical cannabis for the treatment of chronic pain and sleep difficulties, needing requirement of long term medical care services
- In 2021, according to Knoema, the population aged 65 years and above in France was 21.1%. The population aged 65 years and above in France increased from 13.2% in 1972 to 21.1% in 2021, growing at an average annual rate of 0.97%
- Rise In incidence of diseases that require the use of cannabis
- Chronic diseases are common health conditions around the world. Globally, one in three adults suffers from chronic conditions. Neurological diseases have affected the health and quality of life of many citizens. Chronic neurological diseases such as Alzheimer’s disease, cancer, inflammatory bowel disease, and epilepsy can lead to hospitalization, long-term disability, reduced quality of life, and death.
- Cannabis is a generic term used to denote the several psychoactive preparations of the plant Cannabis sativa. Cannabis has been used for medicinal or recreational purposes. Since cannabinoids react with receptors in the nervous system, researchers believe cannabinoids may be helpful in treating other neurologic conditions as well. Medical cannabis is safe and effective for improving symptoms such as pain, sleep disorders, and anxiety due to chronic diseases in older adults.
For instance,
- In 2021, the data by Alzheimer's Association stated that more than 1.5 million people in Germany are living with Alzheimer’s disease
- In 2021, the data by Epilepsia states that Austria (616) reported the maximum number of cases of epilepsy, followed by Denmark (482), Ireland (476), and Romania (414)
As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence and incidence of neurodegenerative diseases would help in finding novel solutions that would aid in more collaborations and partnerships with market players in the Europe region. This signifies the increase in research and development-related investments for the discovery, development, and production of medical cannabis, which is expected to boost market growth.
Opportunities
- Strategic Initiatives By Market Players
The need for medications to treat knee disorders in Europe has increased due to the rise in prevalence and incidence of chronic knee disorders, advanced therapies for knee osteoarthritis and meniscal injuries, and unmet medical needs. The factors (such as rise in incidence, cases of chronic knee disorders, and availability of advanced therapies) enhance the necessity for orthopedic rehabilitation therapy, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
For instance,
- In June 2020, Zimmer Biomet received clearance from the Food and Drug Administration (FDA) for ROSA Hip System for Robotically-Assisted Direct Anterior Total Hip Arthroplasty. The clearance received had made the ROSA Hip System available for use by diagnostic centers in Europe and made it clear for post-marketing approval
- In December 2017, amplitude SURGICAL launched the ACLip, an innovation in anterior cruciate ligament (ACL) reconstruction knee surgery. The ACLip is a knee implant that provides surgeons an enhanced method to perform knee arthroscopy surgeries and is used as an outpatient procedure. The launch had increased the sales and revenue of the knee product segment, and the novel implant was distributed in orthopedic clinics in Europe
Hence, these steps taken by manufacturers are acting as a driver for Europe medical cannabis market. These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.
- Novel Product Development with Increasing Research and Development (R & D) Activities
Vigorous growth in the demand for cannabis with the legalization has increased the need to come up with better product strains and delivery systems. This has led many companies to conduct research and development activities to check the genetic improvement strategies for cannabis.
For instance,
- In 2018, Canopy Growth Corporation in Smiths Falls, which is the largest cannabis company in the world, paid more than USD 300.00 million in cash and shares to acquire Ebbu, which is a small company and is the first to develop platforms for manipulating the cannabis genome with the gene-editing system CRISPR–Cas9
- In March 2018, Hydropothecary partnered with Segra in March 2018 to incorporate plant tissue propagation into the cannabis plant production process to help increase the yield of healthy and better variant plants to serve the growing industry for medical and recreational cannabis
- Front Range Biosciences, which was founded in 2015, has raised USD 4.60 million up to 2019. The company is currently producing disease-free, and high-yielding strain clones up to 1 million plants in its facility
The companies are extremely focused on developing large-yielding varieties, improved herbicide tolerance, low THC content, and better harvesting and market qualities of cannabis crops. As the strains are improved, this will lead to the production of a better quality of cannabis, and this will create more demand for good quality seeds. Hence, novel product development is expected to act as an opportunity for the Europe medical cannabis market.
Restraints/Challenges
Long Term and Short Term Side Effects Related to the Use of Cannabis and Cannabis Overuse
Orthopedic specialists observe certain risks while using the implants and consuming the medications. The knee replacement surgeries deliver complications that arise from surgery or a faulty implant. The implant becoming loose is one of the most severe complications after knee surgery, and pain is the most common one. Loosening can cause bone fractures, instability, and serious falls. Almost all serious complications require revision surgery. The risks faced are mechanical risks, knee implant loosening and physical pain.
Marijuana is the second most commonly used psychotropic drug after alcohol. Smoking THC-rich resins, which are extracted from the cannabis plant, is on the rise, and it has caused severe emergency problems for consumers.
THC binds with the specific brain cell receptors to cause several short-term effects such as impaired body movement, altered sense of time, impaired memory, hallucinations, delusions, and psychosis, among many others. It has also been observed in various studies that marijuana affects the process of brain development.
For instance,
- Researchers at Duke University, New Zealand, observed from a study that the people who have started smoking in their teens lost an average of 8 IQ points between the age of 13 and 38.
- In 2022, the European Union stated that around 83 million or 28.9 % of adults (aged 15- 64) in the European Union are projected to have used medical cannabis at least once in their lifetime
- Levels of lifetime use of cannabis differ considerably between countries, ranging from around 4 % of adults in Malta to 45 % in France
- Medical cannabis is the most commonly used tried medication among (47.6 million males and 30.9 million females)
The consumption of marijuana can cause various life-altering effects. With the increasing awareness of the side effects of marijuana and the increasing health consciousness among people, the use of marijuana can be lowered. This acts as an obstacle for the market. Hence, side effects related to the use of cannabis can act as a challenge for the Europe medical cannabis market to grow in the coming years. Hence, these adverse effects associated with the long-term use of cannabis may hamper the Europe medical cannabis market.
- Lack of Skilled Personnel
The cannabis industry is not only facing supply shortages, product restrictions, and stringent regulations but also the skilled personnel which is required to run the industry smoothly. The cannabis industry deals with the emerging candidate concerns along with the shortage of skilled personnel. From the stigma of working with previously banned substances to expertise and security, all these challenges are faced by the industry.
As the companies were facing a shortage of personnel, for instance, Green Leaf Medical said that they are in the process of hiring roughly 300 workers for its cultivation and retail operations as the demand is high and more patients are registered every day, but they are lacking the personnel for management.
Europe medical cannabis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Europe medical cannabis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Europe medical cannabis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Covid-19 Impact on the Europe Medical Cannabis Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to rehabilitation clinics will further affect the market. However, the certification received for use of medical cannabis, during the pandemic, showed a positive growth in the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in the treatment of neurological diseases during the pandemic.
Recent Development
- In May 2020, Tilray announced that it had received GMP certification in accordance with European Union standards which allows the facility to manufacture medical cannabis extracts in-house and can export finished medical cannabis products. This helped the company to expand its business.
Europe Medical Cannabis Market Scope
Europe medical cannabis market is segmented on the basis of product, source, species, derivatives, application, and route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Oil
- Dried Medical Cannabis
- Medical Cannabis Capsules
- Vape Pen
- Whole Flower
- Creams & Moisturizer
- Ground Flower
- Others
On the basis of product the market is segmented into oil, medical cannabis capsules, whole flower, ground flower, vape pen, dried medical cannabis, creams & moisturizer, and others. Oil is further segmented into by type, by source, and by species.
Source
- Natural
- Synthetic
On the basis of source, the market segmented into synthetic and natural.
Species
- Sativa
- Hybrid
- Cannabis Indica
On the basis of species, the market segmented into sativa, hybrid and cannabis indica.
Derivatives
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)/Delta-8-Tetrahydrocannabinol
- Others
On the basis of derivatives, the market segmented into cannabidiol (cbd), tetrahydrocannabinol (THC)/delta-8-tetrahydrocannabinol and others.
Application
- Pain Management
- Anxiety
- Muscle Spasms
- Nausea
- Appetite Loss
- Cancer
- Arthritis
- Alzheimer's Disease/Migraines
- Epilepsy
- Depression and Sleep Disorders
- Multiple Sclerosis
- Autism
- Mental Health Conditions
- Elevate Mood
- Others
On the basis of application, the market segmented into pain management, anxiety, muscle spasms, nausea, appetite loss, cancer, arthritis, Alzheimer’s disease/migraines, epilepsy, depression and sleep disorders, multiple sclerosis, autism, mental health conditions, elevate mood and others.
Route of Administration
- Oral Solution and Capsules
- Smoking
- Topicals
- Vaporizers
- Others
On the basis of application, the market segmented into oral solution and capsules, smoking, topicals, vaporizers and others.
End User
- Homecare Setting
- Hospital
- Rehab Centers
- Pharmaceutical Industry
- Research and Development Centers
- Others
On the basis of end user, the market is segmented into homecare setting, hospital, rehab centers, pharmaceutical industry, research and development centers and others.
Distribution Channel
- B2C
- B2B
On the basis of end user, the market is segmented into B2C and B2B.
Europe Medical Cannabis Market Regional Analysis/Insights
Europe medical cannabis market is analyzed and market size insights and trends are provided by country, testing type, type pf tests, site and application, as referenced above.
The countries covered in the Europe medical cannabis market report are Germany, France, U.K., Spain, Italy, Netherlands, Belgium, Russia, Switzerland and Rest of Europe.
Germany is expected to dominate the market due to rise in knee osteoarthritis, rise in knee arthroplasty surgeries and presence of various orthopedic centers in Germany.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are Considered While Providing Forecast Analysis of the country data.
Competitive Landscape and Europe Medical Cannabis Market Share Analysis
Europe medical cannabis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Europe medical cannabis market.
Some of the major players operating in the Europe medical cannabis market are Tilray, Medipharm Labs, Althea Company Pty Ltd, PharmaHemp, Aurora Cannabis., CANOPY GROWTH CORPORATION, Jazz Pharmaceuticals, Inc., ECOGEN BIOSCIENCES, Little Green Pharma, GRASS & CO., CANNARAY, Sanity Group GmbH., VIVO Cannabis Inc., HEXO Corp., and Marrican Inc., among others.
Research Methodology
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
SKU-